Evaluation of PSMA-based PET as an Imaging Biomarker of Androgen Receptor Signaling in High-Risk localized and Locally Advanced Prostate Cancer
Johns Hopkins Kimmel Cancer Center in Baltimore
This research is being done to see if an investigational radioactive imaging agent (radiotracer) called 18F-DCFPyL can help us find prostate cancer at its original site in the prostate gland and in distant sites (bone, lymph nodes) in men diagnosed with prostate cancer before and after androgen deprivation therapy, also commonly referred to as “hormone therapy”.
To be eligible for this study, patients must be diagnosed with prostate cancer from a prostate biopsy, Patients must be considered as candidates for and medically fit to undergo radiation therapy and androgen deprivation therapy.
Eligible patients will have imaging twice (18F-DCFPyL PET-CT and MRI imaging). Patients will undergo a prostate biopsy before they start the androgen deprivation therapy, patients may not have a prostate biopsy performed if they had a prostate biopsy at Hopkins in the past 180 prior to participating in the study. All patients will undergo a second prostate biopsy after 2-3 months of androgen deprivation therapy and completion of the Imaging visit 18F-DCFPyL PET-CT and MRI imaging.
08/08/2020 05:02 AM